Dan Ives, Wedbush Securities global head of tech research, joins 'Fast Money' to discuss Apple's AI strategy and if it's too ...

CNBC's Steve Kovach and Dan Ives, Wedbush, joins 'Closing Bell' to discuss if Apple's stock move on Wednesday is a necessary ...

Wedbush raised the firm’s price target on Travere Therapeutics (TVTX) to $32 from $30 and keeps an Outperform rating on the ...

The new AI-focused ETF is putting your money where its mouth is, so to speak, by utilizing the very technology it's investing ...

Tesla shares are trading higher Friday. Investors are digesting a flurry of conflicting reports, ultimately focusing on the ...

The Trade Desk reported second-quarter revenue slightly ahead of consensus and adjusted EBITDA of $271 million, beating guidance by about $10 million.

Wedbush analyst David Nierengarten lowered the firm’s price target on Xencor to $26 from $31 and keeps an Outperform rating on the shares following quarterly results. The firm n ...

Wedbush turned bullish on AMC’s stock, citing a more consistent movie-release slate over the next several quarters and prospects for market-share gains.

Wedbush analyst reiterates Apple as Outperform, sees $100B US investment as strategic move to ease tensions and secure growth ...

Detailed price information for Nuvation Bio Inc (NUVB-N) from The Globe and Mail including charting and trades.

Better-than-expected sales and guidance weren’t enough to lift Advanced Micro Devices stock over the high bar set by its ...

AMC Entertainment shares soared after Wedbush Securities upgraded the stock, saying the movie theater chain was "poised to ...